Navigation Links
NeurogesX Reports First Quarter 2008 Results
Date:5/15/2008

Highlights:

- IND for liquid formulation, NGX-1998, expected to be opened and commencement of clinical development expected in second quarter of 2008 - NDA submission for dermal patch, NGX-4010, in PHN expected in second half

of 2008

- NGX-4010 MAA under EMEA review for peripheral neuropathic pain

SAN MATEO, Calif., May 15 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the first quarter of 2008.

Anthony DiTonno, President and CEO, commented, "We are focused on achieving our overall goal of receiving marketing approval for our lead product candidate, NGX-4010 in the United States and Europe. Following our recent meeting with the U.S. Food and Drug Administration (FDA), we believe that we are on track to file a new drug application (NDA) later this year for the postherpetic neuralgia (PHN) indication. Our marketing authorization application (MAA) was accepted by the European Medicines Agency (EMEA) in September of last year under the centralized procedure. We have been granted an extension for our response to the Day 120 questions in order to include additional clinical data and plan to submit our response in the third quarter of 2008."

Mr. DiTonno continued, "During the second quarter of 2008, we plan to open an investigational new drug (IND) application for our second product candidate, NGX-1998, a liquid formulation of capsaicin, the same active ingredient in our lead product candidate, NGX-4010. We are evaluating our clinical program for NGX-1998 in a range of neuropathic pain conditions."

F
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. NeurogesX to Report First Quarter 2008 Financial Results
2. NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
3. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
4. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
5. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
6. NeurogesX Closes $25 Million Private Placement
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
9. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
10. NeurogesX Expands Senior Management Team
11. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... BioTech News Coverage: Progress made ... of studies and trials.  Companies in focus are: GenSpera ... LLY ), Gilead Sciences Inc. (NASDAQ: ... and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) GenSpera, ... for the treatment of cancer, announced that the United ...
(Date:9/19/2014)... 19, 2014 The new , Healthcare ... , available today on PharmaBoardroom.com for free ... that rocked the Spanish economy in 2009, and the austerity ... has remained pragmatic in times of trouble. "Despite ... fifth biggest European market, and the general conditions to invest ...
(Date:9/18/2014)... September 18, 2014 A novel robotic ... MRI scanner is currently being tested as part of ... Hospital in Boston with the aim of determining if ... make prostate cancer biopsies faster, more accurate, less costly, ... also has the potential to deliver prostate cancer therapies ...
(Date:9/18/2014)... -- Research and Markets has announced the ... Industry Report, 2014-2017" report to their offering. ... can differentiate into specialized cells and can divide (through ... can be applied to treatment of cardiovascular diseases, leukemia ... damage or lesion of liver, kidney and other parenchymal ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3
... Netherlands, August 4, 2011 SynCo Bio Partners ... today announced that its aseptic filling facility is again fully ... product batches for its clients after the expansion of its ... Class A zone is an important milestone in SynCo,s strategy ...
... An examination of the world,s largest river basins ... in the blooms of plankton associated with cholera outbreaks. ... increased temperature in coastal water, suggesting that predicting global ... complicated than first thought, according to a new study ...
... Corporation (Nasdaq: DNDN ) today reported results for ... the quarter ended June 30, 2011 was $49.6 million ... 30, 2010.  This included a $1.9 million reserve for ... or other pricing discounts offered pursuant to mandatory federal ...
Cached Biology Technology:SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility 2Scientists pinpoint river flow associated with cholera outbreaks, not just global warming 2Scientists pinpoint river flow associated with cholera outbreaks, not just global warming 3Dendreon Reports Second Quarter 2011 Financial Results 2Dendreon Reports Second Quarter 2011 Financial Results 3Dendreon Reports Second Quarter 2011 Financial Results 4Dendreon Reports Second Quarter 2011 Financial Results 5Dendreon Reports Second Quarter 2011 Financial Results 6Dendreon Reports Second Quarter 2011 Financial Results 7Dendreon Reports Second Quarter 2011 Financial Results 8
(Date:9/18/2014)... Why is it that when people are too stressed ... Researchers from the Brain Mind Institute (BMI) at EPFL ... the relationship between chronic stress and the loss of ... an enzyme attacks a synaptic regulatory molecule in the ... Nature Communications . , Carmen Sandi,s team ...
(Date:9/18/2014)... Becoming invisible is probably the ultimate form of camouflage: ... you. And this strategy is not as uncommon as ... Maryland Baltimore County, USA, explains that the larval life ... is one part of the anatomy that most creatures ... compound eyes have to shield each individual eye unit ...
(Date:9/18/2014)... in the protective tentacles of host anemones, but new ... of kilometres across the open ocean. Although the process ... this is the first time that the high level ... , Dr Steve Simpson, Senior Lecturer in Marine Biology ... colleagues from the Australian Research Council Centre of Excellence ...
Breaking Biology News(10 mins):How stress tears us apart 2Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3
... Medical Center and CardioKinetix Inc., a medical device ... today announced promising results for the first-of-its-kind catheter-based ... Therapy (PVRT) technology for patients with ischemic heart ... were presented today (May 18, 2012, 9 a.m.) ...
... London have shown that zebrafish could be used to ... study, published online in the journal Behavioural Brain ... response to varying situations. Dr Caroline Brennan, from ... led the study, said: "Zebrafish are becoming one of ...
... 2012) By focusing on the identification of ... polymorphisms (SNPs) that predictwith a high degree of certainty--the ... (ASD) will also develop the condition. The findings ... ASD is among the most common form of ...
Cached Biology News:UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure 2UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure 3Zebrafish could hold the key to understanding psychiatric disorders 2Common genetic variants identify autism risk in high risk siblings of children with ASD 2Common genetic variants identify autism risk in high risk siblings of children with ASD 3Common genetic variants identify autism risk in high risk siblings of children with ASD 4
... enzyme-activity assay based on measurenment of enzyme ... antibody coated microtiter plate. The procedure includes ... or controls, 2nd enzyme reaction) separated ... intended for the determination of human enzymaticaly ...
... iEMS Incubator/Shaker HT is designed ... iEMS Incubator/Shaker HT is ideal ... hybridization and primer extension assays. ... as a one-cabinet model, allowing ...
... The iEMS Incubator/Shaker HT is ... the iEMS Incubator/Shaker HT is ... DNA hybridization and primer extension ... available as a one-cabinet model, ...
... is a modified cap analog in which ... is replaced with OCH3. Because of this ... transcription with the remaining hydroxyl group thus ... As a result, unlike transcripts synthesized with ...
Biology Products: